Table 5 Summary of clinical trials targeting BTLA in cancer
From: BTLA biology in cancer: from bench discoveries to clinical potentials
Clinical Trial | Year | Cancer | Phase | Therapy | Status |
|---|---|---|---|---|---|
NCT04137900 | 2019 | Lymphoma, melanoma, NSCLC, RCC, UC or other tumors | Phase I | Monotherapy or combined with Toripalimab | Recruiting |
NCT04278859 | 2020 | Advanced solid tumors | Phase I | Monotherapy | Unknown |
NCT04477772 | 2020 | Recurrent/refractory malignant lymphoma | Phase I | Monotherapy or combined with Toripalimab | Active, not recruiting |
NCT04773951 | 2021 | Melanoma, RCC, UC | Phase I | Monotherapy or combined with Toripalimab | Recruiting |
NCT04929080 | 2021 | HNSCC, NPC | Phase I/II | Monotherapy or combined with Toripalimab | Not recruiting, completed |
NCT05000684 | 2021 | Advanced lung cancer | Phase I/II | Monotherapy or combined with Toripalimab | Recruiting |
NCT05427396 | 2022 | LC, ESCC, GC, cervical cancer, CRC | Phase I | Combined with Toripalimab | Recruiting |
NCT05664971 | 2022 | Advanced lung cancer | Phase Ib/II | Combine with Toripalimab and with chemotherapy | Recruiting |
NCT05789069 | 2023 | RCC, melanoma, NSCLC, GC, CRC | Phase Ia/b | Monotherapy or in combination with tislelizumab | Recruiting |
NCT05891080 | 2023 | Stage III NSCLC | Phase II | Combine with Toripalimab and with chemotherapy | Not yet recruiting |